

Shareholding Pattern

Ipca Laboratories Limited

General Information

Scrip code	524494
NSE Symbol	IPCALAB
MSEI Symbol	NOTLISTED
ISIN	INE571A01038
Whether company is SME	false
Class of Security	Equity Shares
Type of report	Quarterly
Quarter Ended / Half year ended/Date of Report (For Prelisting / Allotment)	30-09-2025
Shareholding pattern filed under	Regulation 31 (1) (b)
Whether the listed entity is Public Sector Undertaking (PSU)?	false

Declaration

Serial No.	Particular	Yes / No	Promoter and Promoter Group	Public shareholder	Non Promoter- Non Public
1	Whether the Listed Entity has issued any partly paid up shares?	false	false	false	false
2	Whether the Listed Entity has issued any Convertible Securities ?	false	false	false	false
3	Whether the Listed Entity has issued any Warrants ?	false	false	false	false
4	Whether Listed Entity has granted any ESOPs, which are outstanding?	false	false	false	false
5	Whether the Listed Entity has any shares against which depository receipts are issued?	false	false	false	false
6	Whether the Listed Entity has any shares in locked-in?	false	false	false	false
7	Whether any shares held by promoters are encumbered under 'Pledge'?	false	false		
8	Whether any shares held by promoters are encumbered under 'Non-Disposal Undertaking'?	false	false		
9	Whether any shares held by promoters are encumbered, other than by way of Pledge or NDU, if any?	false	false		
10	Whether company has equity shares with differential voting rights?	false	false	false	false
11	Whether the listed entity has any significant beneficial owner?	false			

Serial No.	Category & Name of the Shareholders (I)	Category	Category / More than 1 percentage	Bank Name	No of the Shareholders (III)	No. of fully paid up equity shares held (IV)	No. Of Partly paid-up equity shares held (V)	No. Of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities (IX)			No. Of Shares Underlying Outstanding convertible securities (XA)	No. of Shares Underlying Outstanding Warrants (XB)	No. Of Outstanding ESOP Granted (XC)	No. of Shares Underlying Outstanding convertible securities, No. of Warrants and ESOP etc. (X) = (XA+XB+XC)	Total No. of shares on fully diluted basis (including warrants, ESOP, Convertible Securities etc.) (XI) = (VII+X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XII) = (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XIII)		Number of Shares pledged (XIV)		Non-Disposal Undertaken (XV)	
											Class eg: X	Class eg: Y	Total							No. (a)	As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)
	Total (A+B+C)				82870	253704218			253704218	100.00	253704218						253704218	100.00							
Disclosure of notes on shareholding pattern																									
Disclosure of notes in case of promoter holding in dematerialised form is less than 100 percentage																									
Disclosure of notes in case of public share holding is less than 25 percentage																									
Disclosure of notes on shareholding pattern for company remarks explanatory																									

Text Block

[Textual Information\(1\)](#)

Pursuant to an order passed under Section 233 and rule 25 (5) of the Companies Act, 2013, by the Regional Director (WR) Mumbai, Ministry of Corporate Affairs, Paschim Chemicals Private Limited (PCPL) and Mexin Medicaments Private Limited (MMPL), both wholly owned subsidiaries of Kaygee Investments Private Limited (KIPL) as well as Promoters of the Company, have merged with Kaygee Investments Private Limited (KIPL).

Table VI - Statement showing foreign ownership limits

Particular	Approved limits(%)	Limits utilized(%)
As on shareholding date	74.00	10.68
As on the end of previous 1st quarter	74.00	10.92
As on the end of previous 2nd quarter	74.00	11.02
As on the end of previous 3rd quarter	74.00	11.33
As on the end of previous 4th quarter	74.00	11.09